Inovio Pharmaceuticals (INO) Retained Earnings (2010 - 2026)
Inovio Pharmaceuticals (INO) posted Retained Earnings of -$1.8 billion for Q1 2026, down 282048.02% sequentially from -$637963.0 in Q4 2025, and down 5.88% YoY from -$1.9 billion in Q1 2025.
Inovio Pharmaceuticals (INO) Retained Earnings (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Retained Earnings for 17 years, with the latest figure at -$1.8 billion in Q1 2026.
- Quarterly Retained Earnings fell 5.88% year-over-year to -$1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.8 billion (down 5.88% YoY) and the FY2025 annual result came in at -$637963.0, up 99.96% from the prior year.
- Retained Earnings declined to -$1.8 billion in Q1 2026 per INO's latest filing, from -$637963.0 in the prior quarter.
- Over five years, Retained Earnings peaked at $1.8 billion in Q2 2025 and troughed at -$1.8 billion in Q3 2025.
- A 5-year average of -$733.2 million and a median of -$1.4 billion in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings tumbled 524741.49% in 2022, then soared 258044.87% in 2024.
- Over 5 years, Retained Earnings stood at -$698741.0 in 2022, then slumped by 232169.92% to -$1.6 billion in 2023, then slipped by 6.61% to -$1.7 billion in 2024, then soared by 99.96% to -$637963.0 in 2025, then slumped by 282048.02% to -$1.8 billion in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$1.8 billion, -$637963.0, and -$1.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - | 1.85 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.85 Bn |
| Mar 31, 2026 | -1.80 Bn |
| Dec 31, 2025 | -637,963.00 |
| Sep 30, 2025 | -1.80 Bn |
| Jun 30, 2025 | 1.80 Bn |
| Mar 31, 2025 | -1.70 Bn |
| Dec 31, 2024 | -1.73 Bn |
| Sep 30, 2024 | -1.71 Bn |
| Jun 30, 2024 | 1.78 Bn |
| Mar 31, 2024 | -676,214.00 |
| Dec 31, 2023 | -1.62 Bn |
| Sep 30, 2023 | -1.60 Bn |
| Jun 30, 2023 | -691,262.00 |
| Mar 31, 2023 | -582,797.00 |
| Dec 31, 2022 | -698,741.00 |
| Sep 30, 2022 | -1.40 Bn |
| Jun 30, 2022 | -1.40 Bn |
| Mar 31, 2022 | -1.29 Bn |
| Dec 31, 2021 | 1.61 Bn |
| Sep 30, 2021 | -1.10 Bn |